Page last updated: 2024-10-30

lomustine and Leukocytopenia

lomustine has been researched along with Leukocytopenia in 34 studies

Research Excerpts

ExcerptRelevanceReference
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."9.05Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)."9.05Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985)
"Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine."7.66Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."5.05Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)."5.05Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985)
"Sixty-four patients who received at least one cycle of a nitrosourea agent (nimustine or lomustine) and teniposide for recurrent glioma between 2008 and 2012; of these patients, 28 did not receive prophylactic pegfilgrastim (cohort A), and 36 patients received prophylactic pegfilgrastim (cohort B)."3.80Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. ( Atta, J; Franz, K; Lemercier, S; Rieger, J; Steinbach, JP; Sulzbacher, A; Thiepold, AL, 2014)
"Nineteen patients with advanced non-Hodgkin's lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of lomustine (CCNU), cytarabine, and prednisone."3.66Salvage chemotherapy for non-Hodgkin's lymphoma. ( Khoo, RK; Ng, PR; Todd, D, 1982)
"Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine."3.66Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980)
"To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU."2.74High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. ( Deckert, M; Feuerhake, F; Finke, J; Ihorst, G; Illerhaus, G; Marks, R; Müller, F; Ostertag, C, 2009)
"Thirty-five patients with advanced breast cancer refractory to initial chemotherapy were randomized to receive two-drug doxorubicin-CCNU or three-drug doxorubicin-CCNU-vincristine (VCR) treatment."2.65Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. ( Bateman, JR; Block, JB; Chlebowski, RT; Pugh, R; Weiner, JM, 1983)
" The dosage of CCNU was 100 mg/m2 p."2.65The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981)
"It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men."2.64Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976)
"Thirty-two patients with recurrent Hodgkin's disease have been treated with an oral regimen employing lomustine (CCNU, 100 mg/m2 orally on Day 1); etoposide (VP-16, 100 mg/m2 orally on Days 1-3 and 21-23); and methotrexate (30 mg/m2 orally on Days 1, 8, 21, and 28)."1.27Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. ( Coleman, CN; Horning, SJ; Jacobs, C; Lewis, BJ; Rosenberg, SA; Tseng, A, 1987)
"One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy."1.26Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. ( Gamble, JF; Loh, KK; Rodgers, RW; Shullenberger, CC, 1980)
" The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow."1.26Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up. ( Armstrong, DM; Aust, JB; Cruz, AB; Fletcher, WS; Metter, G; Richardson, JD; Wilson, WL, 1976)
" In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status."1.25Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). ( Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-199029 (85.29)18.7374
1990's2 (5.88)18.2507
2000's2 (5.88)29.6817
2010's1 (2.94)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thiepold, AL1
Lemercier, S1
Franz, K1
Atta, J1
Sulzbacher, A1
Steinbach, JP1
Rieger, J1
Illerhaus, G1
Marks, R1
Müller, F1
Ihorst, G1
Feuerhake, F1
Deckert, M1
Ostertag, C1
Finke, J1
Zander, T1
Nettekoven, W1
Kraus, JA1
Pels, H1
Ko, YD1
Vetter, H1
Klockgether, T1
Schlegel, U1
Rodgers, RW1
Gamble, JF1
Loh, KK1
Shullenberger, CC1
Aisner, J1
Whitacre, M1
Van Echo, DA1
Wiernik, PH1
Robustelli della Cuna, G1
Paoletti, P1
Bernardo, G1
Knerich, R1
Butti, G1
Cuzzoni, Q1
Wilson, HE1
Stanley, K1
Vincent, RG1
Mountain, CF1
Sealy, R2
Cohen, M1
Chen, TY1
Batley, F1
Kilman, J1
Kakos, G1
Vasko, J1
Williams, TE1
Tucker, RD2
Chlebowski, RT1
Pugh, R1
Weiner, JM1
Block, JB1
Bateman, JR2
Chahinian, AP2
Green, G1
Holland, JF4
Hansen, HH3
Dombernowsky, P1
Hirsch, FR1
Hansen, M1
Rygård, J1
Selawry, OS2
Pajak, TF3
Spurr, CL1
Falkson, G1
Brunner, K2
Cuttner, J2
Nissen, NI2
Cornwell, GG1
Kochwa, S1
McIntyre, OR1
Glowienka, LP1
Rafla, S1
Silver, RT2
Cooper, MR1
Henderson, E1
Kyle, RA1
Haurani, FI1
Ng, PR1
Todd, D1
Khoo, RK1
Gagliano, RG1
Panettiere, FJ1
Haas, CD1
Baker, L1
Hewlett, J1
Stuckey, WJ1
O'Bryan, RM1
Bottomley, R1
Heilburn, LK1
Carmo-Pereira, J1
Costa, FO1
Pimentel, P1
Henriques, E1
Gershanovich, ML1
Akimov, MA1
Hildebrand, J1
Gangji, D1
Nouwynck, C1
Machin, D1
Zeltzer, PM1
Feig, SA1
Taylor, SG1
Nelson, L1
Baxter, D1
Rosenbaum, C1
Sponzo, RW1
Cunningham, TJ1
Olson, KB1
Horton, J1
Stolinsky, DC1
Bull, FE1
Simon, R2
Carr, DT1
van Wyk, CE1
Mandel, EM1
Jaffrey, IS1
Teirstein, AS1
Maurice, P1
Glidewell, O1
Jacquillat, C1
Carey, R1
Pas, AT1
Cornell, CJ1
Burningham, RA1
Alberto, P1
Barrelet, L1
Chapuis, B1
Garcia, B1
Johnson, RO1
Metter, G2
Wilson, W1
Hill, G1
Krementz, E1
Cedermark, BJ1
Didolkar, MS1
Elias, EG1
Wilson, WL2
Andrews, NC1
Frelick, RW1
Nealon, TF1
Bick, RL1
Adams, T1
Tejada, F1
Eisenberger, MA1
Broder, LA1
Cohen, MH1
Cruz, AB1
Armstrong, DM1
Aust, JB1
Fletcher, WS1
Richardson, JD1
Gridelli, C1
Contegiacomo, A1
Lauria, R1
Gentile, M1
Airoma, G1
De Placido, S1
Perrone, F1
Ferrante, G1
Bianco, AR1
Lahouel, M1
Viotte, G1
Sumereau, E1
Morin, JP1
Fillastre, JP1
Tseng, A1
Jacobs, C1
Coleman, CN1
Horning, SJ1
Lewis, BJ1
Rosenberg, SA1
Bajetta, E1
Buzzoni, R1
Viviani, S1
Vaglini, M1
Nava, M1
Bonadonna, G1
Hess, WA1
Kornblith, PL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy[NCT00989352]Phase 256 participants (Anticipated)Interventional2009-09-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

17 trials available for lomustine and Leukocytopenia

ArticleYear
High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Comb

2009
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxoru

1982
Comparison of chemotherapy alone versus chemotherapy and radiation therapy of extensive small cell carcinoma of the lung.
    Journal of surgical oncology, 1983, Volume: 23, Issue:3

    Topics: Aged; Body Weight; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy,

1983
Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial.
    Cancer, 1983, Aug-15, Volume: 52, Issue:4

    Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Humans;

1983
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1984
Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy.
    Cancer, 1980, Jul-15, Volume: 46, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Top

1980
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
    Cancer, 1981, Jan-01, Volume: 47, Issue:1

    Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S

1981
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
    Cancer, 1982, Nov-01, Volume: 50, Issue:9

    Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female;

1982
Enhancement of bone marrow toxicity of VM-26-CCNU combination by bleomycin.
    Cancer treatment reports, 1977, Volume: 61, Issue:9

    Topics: Adult; Aged; Bleomycin; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combin

1977
Combination chemotherapy of advanced lung cancer: a randomized trial.
    Cancer, 1976, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell;

1976
Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma.
    Cancer, 1978, Volume: 41, Issue:5

    Topics: Clinical Trials as Topic; Female; Hodgkin Disease; Humans; Leukopenia; Lomustine; Lymphoma, Non-Hodg

1978
A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
    European journal of cancer, 1975, Volume: 11, Issue:11

    Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Thera

1975
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Cancer treatment reports, 1976, Volume: 60, Issue:2

    Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal

1976
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms;

1976
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adult; Aged; Altretamine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Eval

1976
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea

1977
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
    American journal of clinical oncology, 1985, Volume: 8, Issue:5

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic

1985

Other Studies

17 other studies available for lomustine and Leukocytopenia

ArticleYear
Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.
    Pharmacotherapy, 2014, Volume: 34, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Disease-Free Sur

2014
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
    Journal of neurology, 2002, Volume: 249, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female

2002
Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.
    Cancer, 1980, Dec-01, Volume: 46, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Dacarbazine; Doxorubicin; Drug Administra

1980
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
    Neurosurgery, 1982, Volume: 11, Issue:3

    Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma;

1982
Salvage chemotherapy for non-Hodgkin's lymphoma.
    Cancer treatment reports, 1982, Volume: 66, Issue:11

    Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Lymphoma;

1982
Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
    Cancer clinical trials, 1981,Winter, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Colonic Neoplasms; Deoxyguanosine; Drug Evaluation; Drug Therapy, Combination; Human

1981
Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.
    Cancer treatment reports, 1980, Volume: 64, Issue:1

    Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged;

1980
[Evaluation of the CCNU-COP regimen for primary refractory and recurrent non-Hodgkin's lymphoma].
    Voprosy onkologii, 1999, Volume: 45, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco

1999
Theophylline-induced lomustine toxicity.
    Lancet (London, England), 1979, Nov-03, Volume: 2, Issue:8149

    Topics: Drug Synergism; Female; Humans; Leukopenia; Lomustine; Middle Aged; Nitrosourea Compounds; Theophyll

1979
Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
    Cancer, 1975, Volume: 36, Issue:4

    Topics: Adult; Brain Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Glioblastom

1975
Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
    Oncology, 1975, Volume: 31, Issue:5-6

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Bronchogenic; Carcinoma, Small Cell;

1975
MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
    Cancer, 1979, Volume: 43, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell;

1979
Treatment of advanced malignancy with CCNU (NSC 79037): a phase II cooperative study with long-term follow up.
    Cancer, 1976, Volume: 38, Issue:3

    Topics: Humans; Leukopenia; Lomustine; Neoplasms; Nitrosourea Compounds; Thrombocytopenia

1976
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.
    Tumori, 1991, Dec-31, Volume: 77, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclo

1991
Haematotoxicity of doxorubicin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and of their association in rats.
    Drugs under experimental and clinical research, 1987, Volume: 13, Issue:10

    Topics: Animals; Blood Cell Count; Body Weight; Creatinine; Doxorubicin; Female; Hemoglobins; Leukopenia; Lo

1987
Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.
    Cancer treatment reports, 1987, Volume: 71, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocol

1987
Combination of lomustine and cimetidine in the treatment of a patient with malignant glioblastoma: a case report.
    Cancer treatment reports, 1985, Volume: 69, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Humans; Leukopenia; Lomustine; Male; Mid

1985